AMGEN Aktie

 

You'll need to generate $12,000 a year in dividends to average $1k per month from Amgen, Pfizer, J&J, AbbVie, and Bristol Myers Squibb....

In the closing of the recent trading day, Amgen (AMGN) stood at $414.87, denoting a +1.82% move from the preceding trading day....

Charlotte, NC (www.aktiencheck.de) - Amgen-Aktienanalyse von Truist: Die Analysten von Truist raten die Aktie von Amgen Inc. (ISIN: US0311621009, WKN: 867900, Ticker-Symbol: AMG, NASDAQ-Symbol: AMGN) weiterhin zu halten und heben das Kursziel von 362 auf 380 USD an. Dies erfolge im Rahmen einer umfassenderen Research-Note mit einem Ausblick auf die Ergebnisse des dritten Quartals und Anpassungen der Bewertungsmodelle für Biotechnologieunternehmen. [mehr]...

In the closing of the recent trading day, Amgen (AMGN) stood at $413.08, denoting a +2.6% move from the preceding trading day....

Nach den neuen Bestmarken von S&P 500 und Nasdaq 100 am Vortag haben Anleger zur Wochenmitte zunächst Gewinne gesichert. Gegenwind kam von den gestiegenen Renditen am Anleihemarkt und den weiterhin hohen Ölpreisen. Beides verstärkte die Sorge, dass der Inflationsdruck zunimmt und die US-Notenbank ihren Zinserhöhungskurs fortsetzt....

Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects....

Arboretum focused on expanding access to clinically-indicated genetic testing to power both better outcomes for patients and genomically-stratified clinical trials for drug developers Current healthcare delivery partners include Advocate Health, Cardiovascular Associates of America, Geisinger Health, and Providence Healthcare $30 million Series A financing led by F-Prime, GV, .406 Ventures, Hims & Hers, Amgen and other industry leadersCAMBRIDGE, Mass.--(BUSINESS WIRE)--Arboretum LifeSciences, Inc., a next-generation molecular information company, launched today with a mission to make precision medicine a reality for some of the most common diseases that impact patients around the world. Founded by leaders in data science from the Broad Institute, Arboretum's approach integrates AI and genetic testing to expand access to genomic medicine for patients and enable recruitment of genomically profiled patients for clinical research partners. “We started Arboretum to solve one of the biggest problems in thera...

One offers a more affordable entry point while the other boasts some of the highest profit margins in the sector. The choice comes down to whether you prioritize income stability or growth potential....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Amgen Inc. researchers have found a clue to one of the more puzzling questions in obesity drug development: How can blocking a hormone help people lose weight when activating the same hormone appears to work, too?...

Amgen just handed income investors another dividend raise, but a mountain of acquisition debt, crumbling legacy drugs, and a billion-dollar obesity bet are all competing for the same pool of cash....

Appointment follows 14 months as Keyron Director and Head of Regulatory Affairs and represents a major strengthening of Board leadership as ForePass® advances toward first-in-human clinical development and the U.S. FDA pathwayLONDON--(BUSINESS WIRE)--Keyron, developer of the ForePass® fully reversible metabolic bypass platform for severe metabolic disease, today announced that David Feigal, MD, was appointed Board Chair effective September 21, 2026. Dr Feigal will continue to lead Keyron's regulatory strategy alongside his new role as Board Chair. He is the former Director of the U.S. Food and Drug Administration's Center for Devices and Radiological Health (CDRH), which regulates medical devices in the United States. He led CDRH for five years during a 12-year FDA career spanning senior leadership across devices, biologics and drugs. After the FDA, Dr Feigal held senior global regulatory leadership roles at Amgen and Elan Pharmaceuticals and became a Founding Partner of NDA Partners, advising medical...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Microsoft, Bloom Energy and Amgen highlight Zacks' latest market moves, with strong gains across Focus List, recommendation and dividend portfolios....

In the latest trading session, Amgen (AMGN) closed at $414.61, marking a +2.11% move from the previous day....

Rising Treasury yields are reshaping market preferences, putting dividend growth stocks like EnerSys and Amgen in focus for income and growth....

Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store....

Bengaluru team will support global technology, manufacturing and financial services companies including Microsoft, Meta, Amazon, Goldman Sachs, Amgen and many other multinational enterprises as they navigate India's market structure, regulatory complexity, litigation exposure and platform......

Amgen's dazodalibep meets its primary goal in a Phase III study, showing sustained improvement in systemic Sjogren's disease activity through week 48....

With 190 live customers and 14 top 20 biopharma commitments, Vault CRM is the fastest path to AI PLEASANTON, Calif., Sept. 23, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced a new top 20 biopharma commitment, adding to recent selections by Amgen, Biogen, Eli Lilly and......